News

The Australasian Leukaemia & Lymphoma Group (ALLG) has released its 2025 Research Report, showcasing significant progress in blood cancer research and clinical trial activity. The 2025 Research Report highlights key achievements across collaborative studies, translational science, and patient-focused outcomes, along with insights from leading researchers and scientific experts, including the ALLG Scientific Advisory Committee, Standing Member Committees, and Scientific Working Parties.

Blood cancers are highly complex diseases that present major treatment challenges for clinicians, patients, and their families. Unlike many other cancers, there are currently no screening programs or proven prevention strategies available.

Visit ALLG to learn more.

Strengthening Research Across Australasia & Globally

Throughout 2025, ALLG expanded our research footprint across Australasia and globally by bringing together clinicians, scientists and health care professionals. This collaborative approach has strengthened the quality and reach of ongoing trials, ensuring patients have access to cutting-edge treatment options. The 2025 Research Report highlights our role in advancing high-impact clinical trials and innovative therapies to improve patient outcomes.

Key Highlights from the Research Report

The 2025 Research Report outlines several major developments, including:

• Expansion of multi-centred clinical trials
• Increased patient participation across studies
• Progress in novel therapies for leukaemia and lymphoma
• Strengthened partnerships with global research networks

These milestones reflect a sustained commitment to improving survival rates, treatment and care for patients affected by blood cancer.

Driving Innovation in Blood Cancer Research

A central focus of the year as been accelerating the translation of laboratory discoveries into clinical applications. The 2025 Research Report emphasises advancements in precision medicine, targeted therapies, and improved trial design aimed at delivering more personalised care.

Since 1973, ALLG has supported more to access the best available treatments, while continuing to influence global standards of care. This work remains central to our mission of Better treatments… Better lives.

Looking Ahead

Building on the momentum of 2025, ALLG is set to continue its focus on innovation, collaboration, and patient-centred research. Future initiatives will aim to further enhance trial accessibility and accelerate next-generation therapies.

Visit allg.org.au to learn more.